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About 20% of pregnancies are affected by some form of complication. Research has shown that anomalies
in implantation, development, and growth of the fetus; ineffective nutrient exchange between mother
and fetus due to placental dysfunction; and maternal problems such as hypertension or infection during
pregnancy can all lead to adverse pregnancy outcomes. However, the molecular aetiology of such events
remains poorly understood. Fetal growth restriction (FGR), recurrent miscarriage (RM), preterm birth
(PTB), and pre-eclampsia (PE) are the most common pregnancy complications encountered in the UK and
these outcomes can result in an array of morbidities in both mother and baby, and in the most severe
cases in mortality. We need to know more about normal pregnancy and where the important triggers are
for failure. This prompted us to collect a large set of biological samples with matching clinical data from
over 2500 normal and abnormal pregnancies, for use in research into these conditions. This paper
outlines the nature of these sample sets and their availability to academia and industry, with the
intention that their widespread use in research will make signiﬁcant contributions to the improvement
of maternal and fetal health worldwide (http://www.ucl.ac.uk/tapb/sample-and-data-collections-at-ucl/
biobanks-ucl/baby-biobank).
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Each year, tens of thousands of women in the UK, and millions
across the world, encounter mild to life-threatening pregnancy
complications. Despite substantial developments in the clinical
management and biological understanding of such cases, many
questions regarding the molecular aetiology of common compli-
cations in pregnancy remain unanswered. A key challenge often
associated with research into pregnancy is obtaining sufﬁcient
numbers of biological samples to conduct well-powered studies.
The Baby Bio Bank (BBB) is a large, UK based biobank that was set
up to remove the obstacle of recruitment and to support research
into the environmental and genetic mechanisms underlying com-
mon complications of pregnancy. The BBB provides ethically
approved, high-quality biological samples and clinical data to ac-
ademic and industrial partners, both nationally and internationally.ier Ltd. This is an open access articFunded primarily through the UK based charity, Wellbeing of
Women, the BBB began recruiting pregnant mothers from three
hospitals across London in 2009. The project's recruitment phase
has now reached completion, amassing over 54,000 biological
samples from 2515 healthy and complicated pregnancies.
Recruitment and sample collection was based at three London
hospitals: Queen Charlotte and Chelsea (QC), Chelsea and West-
minster (CW), and St Mary's (SM). Together these London mater-
nity services deliver around 13,000 infants a year. The BBB received
ethical approval for collection from these hospitals from Trent
Derby Research Ethics Committee [1]. Ethical consent for biological
sample collection from the proband (fetus/infant), mother, and
father, as well as access to participating patient records was ob-
tained in advance of the birth. All samples are stored at the UCL
Institute of Child Health, with a duplicate of the entire biobank
located at SM, Imperial College London. Semi-anonymised patient
data, downloaded directly from electronic clinical records and
supplemented by data gathered by the BBB recruitment team (see
S6 for questionnaire format used), is stored in a secure, customle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fetal growth restriction (FGR), pre-eclampsia (PE), preterm birth
(PTB) and recurrent miscarriage (RM) were chosen as the primary
foci for the BBB on account of their prevalence within the UK, but
also because they capture a physiological spectrum of pregnancy
disorders. These disorders are all considered multifactorial, caused
by the combined and varying effects of the maternal and fetal ge-
notype, the intrauterine environment, and many other clinical and
environmental factors. It is thought likely that many issues
covering abnormal implantation to preterm membrane rupture
and delivery may share similar or overlapping aetiologies,
including physiological mechanisms, pathways and even speciﬁc
genetic predisposition variants.
The BBB contains data and paired biological samples from 236
FGR, 133 PE, 373 PTB, and 232 RM pregnancies. Over 1500 ‘normal’
pregnancies with none of the above complications were also
collected for use as control samples, and 636 of these are classiﬁed
as ‘perfect’ controls with no recorded problems associated with the
mothers' health, pregnancy, or delivery.
A unique and valuable aspect of this dataset is the compre-
hensiveness of the paternal samples and clinical data that has been
amassed, accompanying 68% of the participating pregnancies.
Availability of these samples enables investigators interested in
genetic contributions to common pregnancy complications to
conduct powerful genetic studies using traditional trio designs, or
to study in isolation the paternal contribution to pregnancy and
fetal outcome.
This paper summarises the design, recruitment, and main de-
mographic and clinical characteristics of the BBB cohort, and pro-
vides researchers with contact details to enquire about availability
for sample groups of interest. Detailed information regarding
sample collection, preparation, and storage are available in
Supplementary Information.
2. Recruitment design
On account of the expertise of the BBB's founders and the likely
high contribution of genetic factors to the phenotypes of interest,
the BBB was principally conceptualised as a genetic and epigenetic
resource. However, additional opportunities for biomarker research
are available due to the parallel collection of plasma/sera from
mothers, fathers and infants, in addition to urine from the mother.
Recruitment for the BBB was carried out over a four-year period
at three hospitals (SM, CW, QC), following a targeted prospective
cohort design (Fig. 1). Where possible, recruitment occurred at the
antenatal clinic or at follow-up appointments when conditions of
interest ﬁrst presented. This normally gave participants at least
several days to ask questions about the consent form and infor-
mation leaﬂets. Some women were also recruited on antenatal and
labour wards. Any consenting family having a baby at one of the
participating units was able to contribute.
Given the ambitious size of the project, a variety of strategies
were employed to ensure that recruitment to each complication
was as high as possible, whilst still ensuring that they were
recruited prior to delivery. Many women were targeted for
recruitment if deemed to be at risk for a particular complication.
For example, women belonging to certain risk groups (e.g. with a
hypertensive disorder, or complicated pregnancy history) were
approached by recruiters. Nurses and clinicians would also notify
recruiters when women began presenting with clinical symptoms
of a complication, regardless of prior risk status (e.g. at the onset of
pre-eclampsia or following preterm membrane rupture). In addi-
tion, a large number of normal, uncomplicated pregnancies were
also recruited for comparative purposes, with some of thesepregnancies ultimately contributing to the complications groups
(e.g. a woman with no known complication at the time of recruit-
ment could end up delivering preterm).
This process was designed to be feasible within a routine clinical
setting. Whereas a simple randomised or stratiﬁed randomised
design would have been theoretically preferable in minimising
selection bias, this was not possible given the context and the re-
sources at hand.
The BBB recruitment team consisted of three full-time re-
cruiters: two research associates with international experience in
recruitment and research, and one research nurse with substantial
experience of recruitment to large cohort collections, all of whom
were trained phlebotomists and had expertise in the necessary
sample preparation techniques. Each recruiter was based at one of
the three hospitals taking part in the project. The recruiters were
responsible for counselling and obtaining consent from the parents,
as well as collecting and preparing samples around the clock.
Recruitment numbers for each hospital are listed in Table 1.
Recruitment was initiated at SM, before recruitment commenced at
CW, followed by QC.
3. Sample collection and storage
The variety of samples (and relevant accompanying informa-
tion) that were intended for collection from each pregnancy are
presented in Table 2. Recruiters focused on securing the collection
of ‘Trio’ sample sets, inwhich tissue, DNA, and RNA are available for
mother, father, and baby. This aim was achieved for 1328 preg-
nancies in total, across all of the complications and control preg-
nancies. If we assume a dominant model of inheritance for a
potential genetic trait of interest, and a signiﬁcance threshold of 5%,
these trio numbers within the BBB would have reasonable power
(>0.7) to detect risk variants with relative risks above 1.5, if all cases
are combined into one larger ‘complications group’ (under the
hypothesis that certain variants may affect all complications), or
2e2.5 if case groups are considered individually (see S5 for further
details).
Each recruitment centre took responsibility for sample receipt
and storage. Samples received were matched with the clinical
phenotype data and barcoded at point of entry. All tissue and blood
samples are stored at 80 C until requested, with tissue stored in
RNAlater. DNA and RNA are stored at80 C and are available for all
samples in which the relevant primary tissue is available.
Each placenta was collected at birth and processed as quickly as
possible (normally within one hour). Four 1 cm3 sections were
excised from beneath the placental membrane, equidistant from
the umbilical cord and washed in PBS to remove excess maternal
blood. Collecting multiple samples from each placenta increased
the total amount of tissue available, as well as facilitating in-
vestigations into variation in gene/protein expression in different
parts of placenta. By taking samples from four distinct sites,
mosaicism can be detected by standard karyotyping. Placental
mosaicism is present in approximately 2% of chorionic villous
samples [2] and it is likely that a number of such samples will be
present in our collection. In addition to sampling from the chorionic
plate, villous tissue from the maternal side of the placenta, as well
as umbilical cord, cord blood, and fetal membrane tissue were also
collected where possible. All tissue was immediately transferred to
a vile containing RNAlater to minimise degradation of nucleic acids.
Occasionally the placenta, cord or cord blood were not available
(e.g. a baby was delivered at home, in an emergency, or another
hospital). In such instances a buccal swab from the baby was
requested and DNA extracted from this specimen. Buccal swabs for
DNA extraction were also taken from fathers where blood was
unavailable.
Fig. 1. Flow-diagram outlining BBB recruitment and sample collection process.
Table 1
Hospital recruitment rates.
Hospital N (%)
St Mary's 1107 (44)
Chelsea and Westminster 880 (35)
Queens Charlotte's and Chelsea 528 (21)
Table 2
Variety of samples collected from participating trios.
Sample type
Maternal whole blood/serum/plasma
Paternal whole blood/serum/plasma
Maternal urine
Maternal DNA and RNA (from blood/buccal swab)
Paternal DNA and RNA (from blood/buccal swab)
Placental parenchyma, villous, and membrane
Cord blood
Umbilical cord tissue
Baby DNA and RNA (from placenta/buccal swab)
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mising the number of blood draws/hospital visits for mothers,
maternal blood and urine samples were collected once during
pregnancy, at a time that was convenient to the mother, and were
not restricted to a certain time point in gestation. This usually
coincidedwith hospital appointments and blood draws being taken
for clinical purposes. Plasma and serum were extracted immedi-
ately from such samples (see S2 for detailed protocol). Where
possible, approximately 20 ml of blood was collected from each of
the parents. Whole blood, serum and plasma were aliquoted into
maximum volumes of 2 ml to minimise exposure of samples to
freeze-thaw cycles. Urine was collected in standard specimen
containers by the donor and aliquoted into 2ml volumeswithin 1 h,
for long-term storage at 80 C. Given the expected high yields of
DNA from the protocols used for extraction, and the volume of
samples collected, tens of thousands of standard molecular ana-
lyses will be possible using the amount of DNA and RNA available
within the bank.
Maternal blood collection ranged from 7 weeks gestation until
delivery, with the mean gestational age for collection being 25
weeks. Bloods are available for points collected throughout preg-
nancy, with peaks at certain times, such as week 12which coincides
with a key antenatal hospital visit for mothers in the UK (Fig. 2).20% of blood samples were collected within the 1st trimester, 38%
in the 2nd, and 42% in the 3rd. BBB sample requests can be speciﬁed
by gestational age. As maternal samples were collected once from
each pregnancy, consecutive samples are not available. We recog-
nise that this, and the variation in time points of blood collection,
would be a limitation for certain biomarker studies, however this
maximised the number of participants within the study.
To ensure biological samples were processed and maintained to
the highest possible standards necessary for use across all common
molecular applications, detailed quality control audits using PCR,
sequencing, and nucleic acid integrity assessment with the Agilent
2200 TapeStation System, have been conducted on a random se-
lection of at least 15% of the whole cohort. These tests have assured
high purity and integrity of DNA and RNA extracted from BBB
samples, supporting their use in standard molecular biology assays
including Sanger sequencing, qPCR and end-point PCR in which all
samples tested positive for housekeeping genes used as standards.
A number of samples have also been used successfully for exome
analyses and genome-wide methylation assays, in which high DNA
quality and integrity is essential.
Both informal and formal audits of the BBB were conducted.
Informal audits were conducted by the BBB manager. Formal audits
were carried out annually by both the UCL and Imperial Human
Tissue Authority committees respectively. On all audits there was
100% concordance with samples in the electronic database and the
physical location of samples. This was seen in both directions (from
database to sample and sample to database). Retrieval of consent
forms for all samples was also 100%.
4. Clinical and demographic characteristics
Pregnancy related morbidity and mortality are known to be
associated with various neonatal and maternal characteristics that
are well documented in the BBB, and may be of interest either as
the central phenotype under investigation or in downstream
multivariable analyses. To ensure the BBB clinical database was as
comprehensive as possible, data were collected by recruiters using
standardised forms in addition to detailed clinical downloads from
electronic maternity records at each hospital. The two collections
were subsequently merged by the BBB data manager into a format
that is available to BBB users. This design enabled the collection of
certain additional maternal data (e.g. occupation) as well as
paternal data, which were not available on clinical records. This
strategy also allowed for discrepancies in data entry to be identiﬁed
and corrected via comparison of any duplicate categories. A
Fig. 2. Graph showing distribution of gestational ages at maternal blood sampling within the BBB.
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are listed in Table 3. A full list of clinical data categories is available
on request.
The original project aimed to collect only pregnancies from
white European mothers and as can be seen (Table 4) this remains
the largest group within the BBB. However, due to the multina-
tional population in London it proved difﬁcult to identify and
consent a strictly white European cohort. Many clinics were
attended by individuals of Asian and African origin expressing an
interest in participating in the BBB. We were aware that such a
valuable resourcewould be of greater value if it were inclusive of all
ethnic backgrounds and ultimately included such individuals in the
hope that funding would one day be available to cover a similarly
sized cohort collection for these ethnic groups too.
Ethnicity can be grouped in numerous ways and there is often a
lack of consensus within clinical and research communities on
precisely how to do this. The BBB electronic database contains two
separate data columns on maternal ethnicity, that are used widelyTable 3
Selection of clinical information available.
Maternal Paternal Fetal
Agea,b Agea Genderb
BMIb Heighta,c Gestationb
Height b,c Weighta,c Birthweightb
Weight b,c BMIc Placental Weightc
Ethnicityb Ethnicitya Head Circumferenceb
Pre-Pregnancy Weighta Diabetesa Birth Lengthb
Paritya,b Hypertensiona Apgar Scoreb
Diabetesa,b Smokinga Mode Of Deliveryb
Hypertensiona,b Medicationa Congenital abnormalitiesb
Smokinga,b Occupationa
Medicationa,b
Occupationa,b
Pregnancy historya,b
Age at menarchea,b
Marital statusa,b
Infectious diseaseb
a Information volunteered from patient to recruitment staff.
b Information gathered from clinical records.
c Measured by recruiting staff.throughout the NHS and are based on those used in the national
census. Ethnicity data is summarized into four broad categories to
give the reader an idea of the ethnic distribution within the BBB
cohort. The main demographic characteristics of currently available
clinical data of the cohort are outlined in Table 4. Some categories,
e.g. delivery method, have larger amounts of missing data than
others. The further population of these missing ﬁelds is ongoing,
requiring the interrogation of paper rather than electronic notes.5. Deﬁnitions and veriﬁcation of outcome data.
Clinical diagnosis of FGR, PE, RM and PTB is recorded for all our
samples, the deﬁnitions for each of these complications were
consistent across the three NHS hospitals from which our samples
were collected and are outlined below. However, we recognise that
researchers may have speciﬁc deﬁnitions to categorise clinical
complications. To address this, each BBB sample is linked to, and
can be searched by more than 200 ﬁelds of data that we hold,
enabling bespoke categorisation of sample sets, as well as a deeper
analysis of data by the creation of sub-categories as required.
Whilst this potential for sub-categorisation is a valuable feature of
the Bank, we recognise that any such manipulation of the cohort is
limited by the original clinical deﬁnitions used during recruitment,
as stipulated in the following sections.6. Preterm birth
Prematurity affects between 5 and 18% of births worldwide and
is the leading cause of neonatal death globally [3]. In the UK, around
7% of births are preterm [4]. Prematurity is associated with a
complex array of morbidities from neurodevelopmental issues, to
gastrointestinal complications that often extend beyond the
neonatal period, through childhood and into adulthood [5]. Pre-
term births in the BBB were deﬁned as any delivery occurring
before 37 weeks gestation.
Biological samples were collected from the 373 preterm preg-
nancies within the BBB, 122 of which were trios. To achieve this
sizeable collection, recruiters actively targeted mothers with a
history of preterm birth, women presenting with spontaneous
Table 4
Demographic characteristics of the BBB cohort.
Variable Category N (%) Range (SD) Mean
Maternal ethnicity White 1565 (68.2)
Black 229 (10.0)
Asian 99 (4.3)
Otherb 401 (17.5)
Maternal smoking Non-smoker 2074 (87.7)
Smoker 100 (4.2)
Quit within last 12 months 190 (8.1)
Maternal age at booking <20 25 (1.3) 14e55 (5.48) 32.83
20e25 187 (9.6)
26e30 372 (19.1)
31e35 741 (38.0)
36e40 478 (24.5)
41e45 140 (7.2)
>46 6 (0.3)
Maternal BMI at booking <18.5 (Underweight) 71 (3.0) 14e66 (5.27) 24.87
18.5e24.9 (Normal weight) 1304 (55.3)
25.0e29.9 (Pre-obesity) 630 (26.7)
30.0e34.9 (Obesity Class 1) 217 (9.2)
35e39.9 (Obesity Class 2) 94 (4.0)
Above 40 (Obesity Class 3) 42 (1.8)
Maternal parity Nulliparous 1324 (53.5) 0e12 (0.95) 0.67
Primiparous 797 (32.2)
Multiparous 354 (14.3)
Neonate gender Male 1182 (52.0)
Female 1092 (48.0)
Number of infants Singletons 2445 (97.2)
Twins 70 (2.7)
Delivery method CS 716 (42.2)
Vaginal 980 (57.8)
Birthweight (g) 295e5470 (728.92) 3164
GA at birth (weeks)a 20e43 (2.81) 38.32
a Assessed from ultra-sound scanning.
b Chinese, other Asian, other black, other, and all mixed groups.
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with shortened cervices, or those with a positive fetal ﬁbronectin
result. Research into the underlying aetiology of preterm birth
often focuses on the most extreme ‘very early preterm’ cases in
order to best elucidate underlyingmechanisms. Generally classiﬁed
as those born at less than 33 weeks gestation, these births are also
the hardest to collect biological material from, given the compli-
cated nature of such deliveries. The BBB has managed to secure
biological and clinical data from 96 such valuable cases.
The mean gestational age at birth for this group (Table 5) is 33
weeks and the youngest delivery was at just 20 weeks gestation, 3
weeks below the current ‘limit of viability’ upheld by obstetricians
[6]. PTB is often split into three main phenotypic categories for
research: spontaneous, indicated and preterm premature rupture
of membranes (PPROM). The numbers of pregnancies within each
of these sub-categories are also displayed in Table 5. This sub-
categorisation was carried out with reference to data from clinical
records that provided labour, membrane rupture and delivery in-
formation. Deﬁnitions used for categorisation are listed below
Table 5. The BBB preterm deliveries were fairly evenly distributed
between the three main modes of delivery: emergency caesarean
section (CS), elective CS, and vaginal.
7. Pre-eclampsia
PE is a multisystem disorder that affects around 2e8% of preg-
nancies globally [7e9]. Patients typically present with hyperten-
sion during pregnancy in conjunction with proteinuria. The
condition tends to affect women in the latter half of pregnancy and
is associated with both FGR and PTB. PE is estimated to account for
10e15% of all global maternal mortality, with women in developing
countries bearing the vast majority of this burden [10].In our cohort, pre-eclampsia was diagnosed as new hyperten-
sion, i.e. at least two consecutive blood pressure (BP) readings
above 140/90 mmHg or an increase in systolic BP of at least
30 mmHg or diastolic BP of at least 15 mmHg above booking,
combined with new proteinuria deﬁned as a protein creatinine
ratio (PCR) of greater than 50, or 24 h quantitation with a level of
greater than 300 mg. These diagnoses were recorded in the clinical
notes and available to BBB recruiters and data managers for sub-
sequent categorisation. Womenwho had personal or family history
of PE, displayed one or more of the symptoms of the disorder, or
were being actively monitored or treated for it were targeted by the
recruitment team.
The BBB recruited 133 women who went on to have a pre-
eclamptic pregnancy, from which over 700 biological samples
were accrued. 41 of these pregnancies were collected as trios. 45 of
these women also delivered preterm, representing an important
sub-phenotype of the syndrome. As well as women with clinically
diagnosed PE, the BBB also contains a substantial number of
women with PE associated symptoms such as pregnancy induced
hypertension (PIH) or renal complications (as identiﬁed from
maternal clinical records). The number of pregnancies associated
with these morbidities within the BBB are summarized in Table 6.
8. Fetal growth restriction
FGR describes the condition of a fetus unable to reach its growth
potential [11,12], which often results in a small for gestational age
(SGA) baby. SGA is deﬁned as a birthweight for gestational age
below the 10th centile and is often used as a proxy for FGR during
pregnancy. In high-income countries, FGR affects about 5e6% of
pregnancies [13e16]. FGR is associated with perinatal morbidity
and mortality. Furthermore, survivors are at risk for adult-onset
Table 5
Number of preterm pregnancies according to gestational age and mode of delivery.
Preterm birth data (cumulative N)
Gestational age at birth
(weeks)
Total Spontaneous
PTBa
Spontaneous onset of
labourb
PPROMc Indicated
PTB
Missing data on labour/
membrane
Caesarean section
deliveryd
Vaginal
delivery
Induced
labour
20 1 1 0 1 0 0 0 0 1
21 1 0 0 1 0 1 0 0 1
22 2 0 0 1 0 2 0 0 1
23 4 0 3 4 0 4 0 3 1
24 6 0 4 5 1 5 0 5 2
25 16 8 6 8 2 6 2 7 2
26 15 11 9 10 4 0 6 8 2
27 30 17 16 15 6 7 9 12 3
28 33 22 19 20 11 0 17 14 3
29 41 24 21 21 17 0 24 15 3
30 61 30 27 25 21 10 31 17 3
31 80 37 33 31 32 11 40 20 3
32 96 44 39 36 40 12 49 25 3
33 132 58 51 47 60 14 73 32 3
34 186 80 70 64 86 20 94 43 6
35 252 102 87 85 124 26 121 68 21
36 373 145 113 123 186 42 172 105 48
a Spontaneous labour and/or membrane rupture and delivery before 37 weeks.
b Labour is spontaneous and delivery occurs before 37 weeks.
c Membrane rupture is spontaneous and resultant delivery occurs before 37 weeks.
d Emergency and elective.
Table 6
Number of pregnancies associated with a pre-eclamptic phenotype.
Pre-eclampsia phenotype BBB N
Pre-eclampsia 133
PIH 57
PIH in previous pregnancy/ies 76
Essential hypertension 98
Cardiac complications 15
Renal complications 16
Thrombosis 8
Table 7
Distribution of centiles and mean birthweight across the BBB.
Centile BBB N Mean birthweight (g)
<5th 112 1555
5th-<10th 122 2179
10th -< 25th 576 2614
25th-<50th 410 2876
50th-<75th 401 3273
75th-<90th 273 3590
90th-<95th 143 3913
>95th 206 4122
Data not available 272 NA
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[17e20].
Although the original intention was to establish a pure FGR
cohort, we have chosen to use a broader deﬁnition of growth re-
striction in this summary paper, and report here the characteristics
of SGA infants within the BBB, whose birthweight for age centile (as
deﬁned by the 1996 gender speciﬁc four-in-one growth charts
produced by the Child Growth Foundation, London) fell below the
10th centile. Whilst we are aware of the limitations that this deﬁ-
nition holds as a proxy for all FGR pregnancies, with the current
debate surrounding deﬁnitions of FGR and variations in clinical
diagnoses we decided to use this looser deﬁnition under the
assumption that a large number of these SGA babies would indeed
be true cases of FGR. Furthermore, more detailed clinical data from
the pregnancy, including from ultra-sound scans that enable the
mapping of growth trajectories, can be retrieved if a more conser-
vative and strict deﬁnition of FGR is required by BBB users.
The BBB recruited 234 women with babies that fell below the
10th birthweight for gestational age centile. 82 of these deliveries
were successfully recruited as trios. Within this group, 112 babies
were below the 5th birthweight centile and 50% delivered preterm.
The mean birthweight for this SGA cohort was 1880g. The distri-
bution of birthweight for age centiles within the BBB, alongside the
mean birthweight for each centile grouping are summarized in
Table 7.
Alongside interest in the physiological, genetic and environ-
mental underpinnings of FGR, there is now a growing interest in
deliveries at the other end of the spectrum in which neonates arelarge for gestational age, known as macrosomia. Over 200 babies in
the BBB were born above the 95th birthweight for age centile and
over 300 were above the 90th centile. This group poses particular
risks to mothers during delivery and is an important phenotype to
study in attempts to minimise maternal morbidity and mortality
related to childbirth.
9. Recurrent miscarriage
Miscarriage is the commonest complication of pregnancy and is
deﬁned as the spontaneous loss of a fetus before it has reached
viability. Hence, the term miscarriage includes all the losses from
conception up to the 24th week of gestation. Recurrent miscarriage
affects about 1.5% of couples trying to conceive [21]. Studies have
shown that the risk of miscarriage increases after each successive
pregnancy loss and it can reach 45% after three consecutive losses
[22]. Recurrent miscarriage (RM) was deﬁned as three or more
consecutive pregnancy losses, data that was collected from the
clinical records.
The BBB contains samples and clinical data for 232 women who
have a clinical diagnosis of RM, as well as many who have experi-
enced one or two previous miscarriages (Table 8). A large number
of these cases were recruited from the internationally recognized
centre for mothers' suffering from recurrent miscarriage based at
SM and run in part by the BBB principal investigator, LR. 97 of the
RM pregnancies belong to a BBB trio. In total over 1500 mis-
carriages were experienced by women in the cohort, and 770
Table 8
Distribution of number of previous miscarriages within BBB.
No. previous miscarriages BBB N
0 1666
1 399
2 139
3 121
4 55
5 32
6 11
7 7
8 2
9 3
10 1
Data not available 79
Table 9
Summary of extra clinical categories of interest.
Maternal clinical category BBB N
Diabetes 23
Gestational Diabetes 31
Pregnancy from In vitro Fertilization 22
Placenta previa 11
Placental abruption 26
Urinary tract infection 36
Thyroid complications 27
Cardiac complications 29
Epilepsy 48
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pregnancy. 20 women were receiving treatment with aspirin dur-
ing their pregnancy.
10. Other complications
Alongside the four main complications in pregnancy, the size of
the BBB means that a substantial number of other maternal com-
plications were also recorded, as detailed in Table 9.
11. Using the BBB
Interested parties are encouraged to contact the BBB manage-
ment team with any questions or requests they may have relating
to the bank. Procurement of samples is subject to review by the BBB
Research Management Board (who have so far approved all 14
initial applications), as well as written evidence from the applicant
of an ethically approved project for which the samples will be used.
Enquiries should be directed to the BBB Manager, Dr Nita Solanky
(nita.solanky@ucl.ac.uk). Further information on the BBB including
our SOPs, contact details and application form are available at
http://www.ucl.ac.uk/tapb/sample-and-data-collections-at-ucl/
biobanks-ucl/baby-biobank.
Conﬂicts of interest
None.
Acknowledgements
The BBB team would like to thank Wellbeing of Women as well
as all participating hospital staff and families. This research was
funded by the UK Medical Research Council, Biological ResearchCouncil and Great Ormond Street Hospital Children's Charity (LJL
PhD fellowship), and supported by the National Institute for Health
Research Biomedical Research Centre at Great Ormond Street
Hospital for Children, NHS Foundation Trust, and University College
London.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.placenta.2016.08.085.
References
[1] S. Abu-Amero, A. Thomas, S. White, K. Rogers, A. Miranda, N. Solanky, L.J. Leon,
C. Demetriou, X. Ke, S. Stanier, B. Stanier, H. Costello, S. Tzehaie, L. Al-Olabi,
C. Williamson, M. Johnson, L. Regan, G.E. Moore, The Baby Bio Bank-A legacy
for researchers worldwide into common complications of pregnancy,
J. General Pract. 2 (3) (2014).
[2] D.K. Kalousek, M. Vekemans, Conﬁned placental mosaicism, J. Med. Genet. 33
(7) (1996) 529e533.
[3] H. Blencowe, S. Cousens, D. Chou, M. Oestergaard, L. Say, A.B. Moller,
M. Kinney, J. Lawn, the Born Too Soon Preterm Birth Action G., Born Too Soon:
the global epidemiology of 15 million preterm births, Reprod. health 10
(Suppl 1) (2013) S2.
[4] Ofﬁce for National Statistics, Gestation-Speciﬁc Infant Mortality, 2012, p. 2014.
[5] S. Saigal, L.W. Doyle, An overview of mortality and sequelae of preterm birth
from infancy to adulthood, Lancet 371 (9608) (2008) 261e269.
[6] I. Seri, J. Evans, Limits of viability: deﬁnition of the gray zone, J. Perinatol. 28
(S1) (2008) S4eS8.
[7] WHO, Geographic variation in the incidence of hypertension in pregnancy.
World health organization international collaborative study of hypertensive
disorders of pregnancy, Am. J. Obstet. Gynecol. 158 (1) (1988) 80e83.
[8] C.L. Roberts, J.B. Ford, C.S. Algert, S. Antonsen, J. Chalmers, S. Cnattingius,
M. Gokhale, M. Kotelchuck, K.K. Melve, A. Langridge, C. Morris, J.M. Morris,
N. Nassar, J.E. Norman, J. Norrie, H.T. Sørensen, R. Walker, C.J. Weir, Popula-
tion-based trends in pregnancy hypertension and pre-eclampsia: an inter-
national comparative study, BMJ Open 1 (1) (2011).
[9] WHO, WHO Recommendations for Prevention and Treatment of Pre-
eclampsia and Eclampsia, World Health Organization, Geneva, 2011.
[10] L. Duley, The global impact of pre-eclampsia and eclampsia, Semin. Perinatol.
33 (3) (2009) 130e137.
[11] ACOG, Intrauterine growth restriction. Clinical management guidelines for
obstetrician-gynecologists, Int. J. Gynaecol. Obstet. 72 (1) (2001) 85e96.
[12] S.L. Hillman, S. Finer, M.C. Smart, C. Mathews, R. Lowe, V.K. Rakyan,
G.A. Hitman, D.J. Williams, Novel DNA methylation proﬁles associated with
key gene regulation and transcription pathways in blood and placenta of
growth-restricted neonates, Epigenetics 10 (1) (2015) 50e61.
[13] D. Brodsky, H. Christou, Current concepts in intrauterine growth restriction,
J. intensive care Med. 19 (6) (2004) 307e319.
[14] C. Demetriou, S. Abu-Amero, A.C. Thomas, M. Ishida, R. Aggarwal, L. Al-Olabi,
L.J. Leon, J.L. Stafford, A. Syngelaki, D. Peebles, K.H. Nicolaides, L. Regan,
P. Stanier, G.E. Moore, Paternally expressed, imprinted insulin-like growth
factor-2 in chorionic villi correlates signiﬁcantly with birth weight, PloS One 9
(1) (2014) e85454.
[15] G.E. Moore, M. Ishida, C. Demetriou, L. Al-Olabi, L.J. Leon, A.C. Thomas, S. Abu-
Amero, J.M. Frost, J.L. Stafford, Y. Chaoqun, A.J. Duncan, R. Baigel,
M. Brimioulle, I. Iglesias-Platas, S. Apostolidou, R. Aggarwal, J.C. Whittaker,
A. Syngelaki, K.H. Nicolaides, L. Regan, D. Monk, P. Stanier, The role and
interaction of imprinted genes in human fetal growth, Philos. Trans. R. Soc.
Lond. Ser. B Biol. Sci. 370 (1663) (2015) 20140074.
[16] R. Harding, A.D. Bocking, Fetal Growth and Development, Cambridge Uni-
versity Press, Cambridge, 2001.
[17] T. Forsen, J. Eriksson, J. Tuomilehto, A. Reunanen, C. Osmond, D. Barker, The
fetal and childhood growth of persons who develop type 2 diabetes, Ann.
Intern. Med. 133 (3) (2000) 176e182.
[18] R.A. Simmons, Developmental origins of adult disease, Pediatr. Clin. N. Am. 56
(3) (2009) 449e466.
[19] D.J. Barker, Fetal growth and adult disease, Br. J. Obstet. Gynaecol. 99 (4)
(1992) 275e276.
[20] D.J. Barker, C.N. Hales, C.H. Fall, C. Osmond, K. Phipps, P.M. Clark, Type 2 (non-
insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia
(syndrome X): relation to reduced fetal growth, Diabetologia 36 (1) (1993)
62e67.
[21] G.M. Stirrat, Recurrent miscarriage, Lancet 336 (8716) (1990) 673e675.
[22] L. Regan, P.R. Braude, P.L. Trembath, Inﬂuence of past reproductive perfor-
mance on risk of spontaneous abortion, BMJ 299 (6698) (1989) 541e545.
